Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy

Franck Villain; Jean Marie Parel; Katalin Kiss; Richard K. Parish; François Kühne; Yoshiko Takesue; Patrick Hostyn

doi:10.1117/12.147533

Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy

Franck Villain, Jean Marie Parel, Katalin Kiss, Richard K. Parish, François Kühne, Yoshiko Takesue, Patrick Hostyn

Ophthalmology

Research output: Contribution to journal › Conference article

1 Scopus citations

Abstract

Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.

Original language	English (US)
Pages (from-to)	240-244
Number of pages	5
Journal	Proceedings of SPIE - The International Society for Optical Engineering
Volume	1877
DOIs	https://doi.org/10.1117/12.147533
State	Published - Jun 24 1993
Event	Ophthalmic Technologies III 1993 - Los Angeles, United States Duration: Jan 17 1993 → Jan 22 1993

ASJC Scopus subject areas

Electronic, Optical and Magnetic Materials
Condensed Matter Physics
Computer Science Applications
Applied Mathematics
Electrical and Electronic Engineering

Access to Document

10.1117/12.147533

Fingerprint Dive into the research topics of 'Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy'. Together they form a unique fingerprint.

Cite this

Villain, F., Parel, J. M., Kiss, K., Parish, R. K., Kühne, F., Takesue, Y., & Hostyn, P. (1993). Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy. Proceedings of SPIE - The International Society for Optical Engineering, 1877, 240-244. https://doi.org/10.1117/12.147533

Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy. / Villain, Franck; Parel, Jean Marie; Kiss, Katalin; Parish, Richard K.; Kühne, François; Takesue, Yoshiko; Hostyn, Patrick.

In: Proceedings of SPIE - The International Society for Optical Engineering, Vol. 1877, 24.06.1993, p. 240-244.

Research output: Contribution to journal › Conference article

@article{e7b34e2720bc4839a11a2e4db4a14ad3,

title = "Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy",

abstract = "Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.",

author = "Franck Villain and Parel, {Jean Marie} and Katalin Kiss and Parish, {Richard K.} and Fran{\c c}ois K{\"u}hne and Yoshiko Takesue and Patrick Hostyn",

year = "1993",

month = jun,

day = "24",

doi = "10.1117/12.147533",

language = "English (US)",

volume = "1877",

pages = "240--244",

journal = "Proceedings of SPIE - The International Society for Optical Engineering",

issn = "0277-786X",

publisher = "SPIE",

note = "Ophthalmic Technologies III 1993 ; Conference date: 17-01-1993 Through 22-01-1993",

}

TY - JOUR

T1 - Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy

AU - Villain, Franck

AU - Parel, Jean Marie

AU - Kiss, Katalin

AU - Parish, Richard K.

AU - Kühne, François

AU - Takesue, Yoshiko

AU - Hostyn, Patrick

PY - 1993/6/24

Y1 - 1993/6/24

N2 - Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.

AB - Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=9044237851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044237851&partnerID=8YFLogxK

U2 - 10.1117/12.147533

DO - 10.1117/12.147533

M3 - Conference article

AN - SCOPUS:9044237851

VL - 1877

SP - 240

EP - 244

JO - Proceedings of SPIE - The International Society for Optical Engineering

JF - Proceedings of SPIE - The International Society for Optical Engineering

SN - 0277-786X

T2 - Ophthalmic Technologies III 1993

Y2 - 17 January 1993 through 22 January 1993

ER -